The current global response to the COVID-19 pandemic is insufficient in curbing the pandemic; the world is in the midst of a third wave and new strains of the virus are constantly developing. Vaccines are vital to overcome this crisis, but their supply is scarce and the worldwide distribution both inadequate and unequal. Whilst some countries await first vaccine batches, others warm up for potential third doses. In spite of the fact that vaccines were soon crowned ‘global public goods’,¹ little came of it in reality, and low-income countries are dependent on inadequate donation-based systems. Key in changing the tide is to ensure better global access, for which more vaccines must become available. To this end, Intellectual property (IP) rights, know-how and technology must be shared to maximize vaccine production.

中文翻译：

---

COVID-19疫苗是全球公共产品吗？超越花言巧语，致力于共享知识产权、专有技术和技术

当前全球对 COVID-19 大流行的反应不足以遏制大流行；世界正处于第三波浪潮之中，新的病毒株不断发展。疫苗对于克服这场危机至关重要，但它们的供应稀缺，而且全球分布既不充分又不平等。虽然一些国家在等待第一批疫苗，但其他国家正在为可能的第三剂疫苗做准备。尽管事实上，疫苗很快就被冠以“全球公共产品”，^1只小在现实中来的话，低收入国家都依赖于基于不足捐赠的系统。改变潮流的关键是确保更好的全球可及性，为此必须提供更多的疫苗。为此，知识产权 (IP) 权利、专有技术和技术必须共享，以最大限度地提高疫苗生产。